Explore commercial batches, high-purity APIs, and proprietary synthetic peptides produced via validated Solid-Phase Peptide Synthesis (SPPS) under rigorous cGMP protocols.
A rigorous review of Glycyl-L-Histidyl-L-Lysine (GHK), Copper(II) complexation dynamics, epigenetic gene modulation, and tissue remodeling cascades.
GHK resets human genome expressions toward youth and wound repair.
Extreme stability constant prevents toxic unchelated copper release.
Strict single impurity cutoff below 0.1% via orthogonal RP-HPLC.
Automated reactor arrays supporting commercial global procurement.
The tripeptide Glycyl-L-Histidyl-L-Lysine functions as an evolutionary copper chaperone. In its copper(II) chelated state (GHK-Cu, Copper Tripeptide-1, CAS 49557-75-7), the nitrogen of the glycine amino terminal, the amide nitrogen of the histidyl peptide bond, and the imidazole nitrogen coordinate in a planar configuration with Cu²⁺. This square planar complex ensures absolute chelation integrity, eliminating the formation of pro-oxidative free cupric ions during transdermal penetration.
According to Broad Institute Connectivity Map profiling, GHK regulates the expression of over 4,000 human genes. It dramatically upregulates DNA repair genes, suppresses pro-inflammatory cytokines (including TNF-α, IL-6, and TGF-β1), and selectively stimulates Matrix Metalloproteinases (MMPs) while maintaining equilibrium with Tissue Inhibitors of Metalloproteinases (TIMPs). This dual action clears damaged scar collagen and synthesizes pristine pro-collagen Type I and Type III.
Beyond dermal rejuvenation, GHK-Cu exhibits profound stimulation of dermal papilla fibroblasts in androgenetic alopecia models. By blocking DHT-mediated vascular endothelial cell apoptotic cascades and upregulating VEGF and bFGF, GHK expands follicle bulb diameter and converts telogen-phase follicles back into anagenic vigor. For clinical wound management, GHK accelerates tissue re-epithelialization and promotes microvascular angiogenesis without hypertrophic scar development.
Addressing structural bottlenecks, supply chain security, and regulatory fragmentation across major cosmetic, dermatological, and clinical procurement markets.
Premium medical spas, clinical dermatologists, and direct-to-consumer luxury brands require ultra-pure, crystal-stabilized GHK-Cu. Procurement teams must navigate strict California Proposition 65 thresholds on trace heavy metals (lead, arsenic, mercury) while eliminating uncomplexed free copper that degrades serum viscosity and induces oxidation.
EU cosmetics manufacturers demand exhaustive toxicological dossier support, including Ames tests, phototoxicity assays, and in vitro ocular/dermal irritation data. Thinheal supports buyers with full documentation packages for European Cosmetic Product Notification Portal (CPNP) compliance and REACH registration numbers.
In South Korea, Japan, and Greater China, GHK-Cu has witnessed hyper-growth in functional anti-hair-loss tonics and post-laser skin repair formulations. China NMPA safety filings necessitate precise technical submission codes and zero residual organic solvent profiles (Acetonitrile < 410 ppm, DMF < 880 ppm).
Pharmaceutical research teams advancing GHK into diabetic foot ulcer therapeutics, radiation burn dressings, and pulmonary fibrosis clinical trials require cGMP compliance, master batch production records, validation campaigns, and active DMF filings, guaranteed by Thinheal's multi-ton facility.
Transparent benchmark pricing, counter-ion configurations, physical states, and volume escalations for enterprise procurement directors.
| Product Code / CAS | Molecule & Derivative | Target Purity (HPLC) | Counter-Ion / Form | MOQ / Pilot Tier | Commercial Tier (10-50 kg) | Industrial Tier (≥100 kg) | Compliance / Status |
|---|---|---|---|---|---|---|---|
| TH-GHK-01 CAS: 49557-75-7 |
GHK-Cu (Copper Tripeptide-1) Blue Fine Crystalline Powder |
≥ 98.0% | Acetate / Pure Chelate Copper Content: 10.0–12.5% |
$4.80 / g (100g – 1kg) |
$1,850 / kg | Custom Volume Quote | INCI / REACH / NMPA |
| TH-GHK-02 CAS: 49557-75-7 |
GHK-Cu Pharmaceutical Grade Ultra-Low Endotoxin Lyophilisate |
≥ 99.5% | TFA-Free Acetate / Pure Chelate Endotoxin < 0.5 EU/mg |
$12.50 / g (50g – 500g) |
$4,200 / kg | GMP Batch Reserved | USP <85> / EP 2.6.14 |
| TH-GHK-03 CAS: 72957-37-0 |
GHK Free Base (Unchelated) White to Off-White Powder |
≥ 98.5% | Acetate or TFA Salt Net Content > 80% |
$3.90 / g (100g – 1kg) |
$1,550 / kg | Custom Volume Quote | Formulation Base |
| TH-GHK-04 CAS: 299157-54-3 |
Biotinoyl Tripeptide-1 (Biotin-GHK) Hair Growth & Lash Active |
≥ 98.0% | White Microcrystalline High Lipophilic Stability |
$6.20 / g (100g – 1kg) |
$2,450 / kg | Custom Volume Quote | Hair follicle targeted |
| TH-GHK-05 CAS: 147732-56-7 |
Palmitoyl Tripeptide-1 (Pal-GHK) Collagen Booster Active |
≥ 98.0% | White Powder Enhanced Skin Permeation |
$5.50 / g (100g – 1kg) |
$2,100 / kg | High Demand | Global Cosmetic Standard |
* Note on Industrial Economics: Pricing is CIF/DDP delivered, variable based on raw material market index (copper salt derivatives, coupling reagents HATU/HBTU, and amino acid derivatives). Thinheal provides fixed-price annual commercial supply contracts for enterprise commitments above 50 kg/year.
From automated SPPS synthesis lines to dynamic stoichiometric chelation reactors, our Hangzhou facility delivers exceptional batch-to-batch consistency.
Utilizing high-loading 2-Chlorotrityl Chloride Resin or Wang Resin, the synthesis sequence initiates from protected Fmoc-Lys(Boc)-OH, proceeding through stepwise condensation with Fmoc-His(Trt)-OH and Fmoc-Gly-OH. Coupling is driven by advanced carbodiimide/oxyma combinations, achieving coupling conversion yields in excess of 99.6% per amino acid residue and eliminating deletion peptides.
Crude GHK is cleaved utilizing mild TFA/TIS/H2O cocktails. Purification is executed across 300mm industrial dynamic axial compression (DAC) columns packed with 10μm C18 spherical silica. Dual-step linear gradients utilizing pharmaceutical ammonium acetate and pure water isolate the GHK fraction, keeping diastereomeric D-His and D-Lys impurities below 0.15%.
Chelation occurs in automated glass-lined reactors under inert nitrogen blanket. Pharmaceutical-grade Copper(II) basic carbonate or cupric acetate monohydrate is titrated under spectrophotometric monitoring at 630 nm (d-d transition band of GHK-Cu). The reaction maintains an exact 1:1 molar stoichiometry. Lyophilization under ultra-low vacuum yields a non-hygroscopic, vivid blue crystalline active.
Comprehensive Certificate of Analysis (CoA) testing battery deployed across every production lot to guarantee uncompromised purity and regulatory compliance.
| Analytical Test Parameter | Testing Methodology | Acceptance Criteria (Cosmetic Grade) | Acceptance Criteria (cGMP / Pharma Grade) |
|---|---|---|---|
| Identity (Molecular Weight) | Electrospray Ionization MS (ESI-MS) | Consistent with standard: 340.38 (GHK) / 403.92 (GHK-Cu) | Theoretical mass exact match (± 0.2 Da) |
| Purity by HPLC | Reversed-Phase HPLC (UV @ 215 nm & 254 nm) | ≥ 98.0% (Single largest impurity ≤ 1.0%) | ≥ 99.5% (Single largest impurity ≤ 0.1%) |
| Copper Content (in complex) | Inductively Coupled Plasma Mass Spec (ICP-MS) | 10.0% – 12.5% w/w | 10.5% – 11.5% w/w (True 1:1 Chelate) |
| Free Uncomplexed Copper (Cu²⁺) | Spectrophotometric / Ion Chromatography | ≤ 0.5% w/w | ≤ 0.05% w/w (Eliminates degradation in serum) |
| Residual Solvents | Gas Chromatography (GC-Headspace) | Meets USP <467> Option 1 (ACN, DMF, DCM) | Ultra-Low: ACN < 50 ppm, DMF < 50 ppm |
| Heavy Metals (Pb, As, Hg, Cd) | ICP-MS Heavy Metal Panel | Total ≤ 10 ppm (Pb ≤ 2ppm, As ≤ 1ppm) | Total ≤ 2 ppm (Individual ≤ 0.5 ppm) |
| Bacterial Endotoxin | LAL Kinetic Chromogenic Method | Not routinely tested for topical cosmetics | < 0.5 EU/mg (Complies with USP <85>) |
| Bioburden & Pathogens | USP <61> / <62> Microbial Enumeration | Total Aerobic < 100 CFU/g; Yeasts < 10 CFU/g | Sterile or Total < 10 CFU/g; No Pathogens |
A proven, end-to-end development pathway designed to mitigate technical risk, accelerate timelines, and ensure seamless commercial scale-up.
Our computational chemistry and analytical team evaluates target sequences, hydrophobic indices, cleavage liability points, and metal coordination geometry. We optimize amino acid coupling matrices, evaluate side-chain protecting groups (Trt, Boc, Pbf), and define preliminary analytical testing parameters.
Gram-scale pilot batches (100g – 5kg) are executed in pilot SPPS reactors. Our process chemists run fractional factorial DoE to pinpoint optimal cleavage residence times, temperature gradients, and preparative HPLC elution strategies, establishing critical quality attributes (CQAs) and critical process parameters (CPPs).
Scale-up into 500L–2000L synthesis arrays. We execute three consecutive validation batches with exhaustive stability testing (accelerated 40°C/75% RH and long-term 25°C/60% RH). Enterprise clients are provided dedicated inventory reserves, full batch documentation, and regulatory audit accompaniment.
Strategic directions in peptide design, smart transdermal delivery matrices, and sustained-release metal coordination architectures.
Implementation of bio-derived, non-toxic alternative solvents (such as 2-MeTHF and Cyrene) to phase out traditional DMF and NMP in multi-ton SPPS operations. Continuous-flow peptide synthesis platforms integrated with real-time UV and FTIR process analytical technology (PAT) will cut solvent consumption by up to 65% while driving crude purity to new historic highs.
Commercialization of hybrid peptides combining GHK scaffolds with hexapeptide neurotransmitter inhibitors (Argireline-type motifs) and lipophilic anchors (Palmitoyl, Myristoyl). In tandem, cyclic GHK analogs designed to resist endogenous aminopeptidases will provide significantly extended half-lives in systemic and dermal clinical applications.
Deployment of generative protein design algorithms to engineer novel metallopeptide complexes with tailored dissociation kinetics. These intelligent complexes will selectively release copper and zinc ions in response to the microenvironmental pH of diabetic ulcers, radiation necrosis, and photoaged dermis, creating a new paradigm in bioactive skincare and regenerative medicine.
Detailed technical answers addressing formulation stability, analytical specifications, cold chain handling, and regulatory filings.
Color shift from vivid royal blue to green or yellowish-brown typically occurs due to unchelated copper ions undergoing redox reactions, interaction with strong chelators (such as Disodium EDTA), or formulation pH falling below 5.0 or above 7.0. At pH < 4.5, the histidyl imidazole nitrogen protonates, forcing dissociation of the Cu²⁺ complex. Thinheal guarantees ≤0.05% free uncomplexed copper and supplies buffered formulation guidelines to safeguard color stability.
Trifluoroacetic acid (TFA) is a standard cleavage cocktail reagent. However, residual TFA counter-ions can cause localized skin irritation and cellular toxicity in sensitive cosmetic applications. Thinheal utilizes automated ion-exchange chromatography to convert TFA salts into cosmetic-grade Acetate salts, keeping residual TFA below 0.1% or undetectable, conforming strictly to international safety standards.
Bulk lyophilized GHK-Cu powder should be stored in desiccated, amber glass containers or double-polyethylene sealed containers at –20°C for long-term storage (shelf life ≥ 36 months), or at 2°C–8°C for intermediate manufacturing campaigns. Reconstituted aqueous solutions are sensitive to light and aerial oxidation; solutions must be stored protected from light at 2°C–8°C and utilized within 30 to 60 days.
Yes. Hangzhou Thinheal Pharma-Tech provides comprehensive documentation packages for international market registrations. These include batch-specific Certificate of Analysis (CoA) with HPLC and MS profiles, MSDS/SDS in multiple languages, BSE/TSE-free declarations, Cruelty-Free statements, Residual Solvent statements conforming to USP <467>, and China NMPA submission safety code dossiers.
Absolutely. Thinheal specializes in solid-phase peptide derivatization. We routinely produce high-purity Palmitoyl Tripeptide-1 (CAS 147732-56-7), Myristoyl Tripeptide-1, and Biotinoyl Tripeptide-1 (CAS 299157-54-3) at multi-kilogram to ton scale, offering customizable purity grades from 95% to 99% for anti-aging serums and hair-growth treatments.
With our modern production base in Hangzhou, Zhejiang, and automated multi-channel peptide synthesis facilities, Thinheal operates at a multi-ton capacity for chemically synthesized generic and cosmetic peptides. We maintain a constant safety stock of over 200 kg of high-purity GHK-Cu to fulfill immediate client orders within 48 hours.
Explore our specialized portfolio of synthetic peptides, metabolic analogues, and neuroprotective actives developed for high technical barrier clinical formulations.
Whether you require pilot batches for dermal penetration trials or multi-hundred kilogram commercial supply contracts for international skincare lines, Hangzhou Thinheal Pharma-Tech provides verified analytical purity, compliant regulatory dossiers, and competitive wholesale pricing.
Thin
